title: Conjugation of polysaccharide 6B from Streptococcus pneumoniae with pneumococcal surface protein A: PspA conformation and its effect on the immune response.
abstract: Despite the substantial beneficial effects of incorporating the 7-valent pneumococcal conjugate vaccine (PCV7) into immunization programs, serotype replacement has been observed after its widespread use. As there are many serotypes currently documented, the use of a conjugate vaccine relying on protective pneumococcal proteins as active carriers is a promising alternative to expand PCV coverage. In this study, capsular polysaccharide serotype 6B (PS6B) and recombinant pneumococcal surface protein A (rPspA), a well-known protective antigen from Streptococcus pneumoniae, were covalently attached by two conjugation methods. The conjugation methodology developed by our laboratory, employing 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium chloride (DMT-MM) as an activating agent through carboxamide formation, was compared with reductive amination, a classical methodology. DMT-MM-mediated conjugation was shown to be more efficient in coupling PS6B to rPspA clade 1 (rPspA1): 55.0% of PS6B was in the conjugate fraction, whereas 24% was observed in the conjugate fraction with reductive amination. The influence of the conjugation process on the rPspA1 structure was assessed by circular dichroism. According to our results, both conjugation processes reduced the alpha-helical content of rPspA; reduction was more pronounced when the reaction between the polysaccharide capsule and rPspA1 was promoted between the carboxyl groups than the amine groups (46% and 13%, respectively). Regarding the immune response, both conjugates induced functional anti-rPspA1 and anti-PS6B antibodies. These results suggest that the secondary structure of PspA1, as well as its reactive groups (amine or carboxyl) involved in the linkage to PS6B, may not play an important role in eliciting a protective immune response to the antigens.
authors.affiliation: Centro de Biotecnologia, Instituto Butantan, São Paulo, Brazil.
authors.forename: Catia T
authors.initials: CT
authors.lastname: Perciani
authors.forename: Giovana C
authors.initials: GC
authors.lastname: Barazzone
authors.forename: Cibelly
authors.initials: C
authors.lastname: Goulart
authors.forename: Eneas
authors.initials: E
authors.lastname: Carvalho
authors.forename: Joaquin
authors.initials: J
authors.lastname: Cabrera-Crespo
authors.forename: Viviane M
authors.initials: VM
authors.lastname: Gonçalves
authors.forename: Luciana C C
authors.initials: LC
authors.lastname: Leite
authors.forename: Martha M
authors.initials: MM
authors.lastname: Tanizaki
mesh_terms: D000818:Animals; D000907:Antibodies, Bacterial / Q000097:blood*; D001426:Bacterial Proteins / Q000737:chemistry / Q000276:immunology*; D002942:Circular Dichroism; D005260:Female; D006801:Humans; D051379:Mice; D008807:Mice, Inbred BALB C; D022242:Pneumococcal Vaccines / Q000737:chemistry / Q000276:immunology*; D011135:Polysaccharides, Bacterial / Q000737:chemistry / Q000276:immunology*; D011487:Protein Conformation; D013296:Streptococcus pneumoniae / Q000276:immunology*; D018074:Vaccines, Conjugate / Q000737:chemistry / Q000276:immunology; D014614:Vaccines, Synthetic / Q000737:chemistry / Q000276:immunology
chemical_list: D000907:Antibodies, Bacterial; D001426:Bacterial Proteins; D022242:Pneumococcal Vaccines; D011135:Polysaccharides, Bacterial; D018074:Vaccines, Conjugate; D014614:Vaccines, Synthetic; C051592:pneumococcal surface protein A
references.citation: Infect Immun. 2010 May;78(5):2163-72
references.pmid: 20194601
references.citation: Pediatr Infect Dis J. 2009 Apr;28(4 Suppl):S66-76
references.pmid: 19325449
references.citation: J Clin Microbiol. 2006 Aug;44(8):2838-43
references.pmid: 16891500
references.citation: Lancet. 2009 Sep 12;374(9693):893-902
references.pmid: 19748398
references.citation: J Immunol. 1989 Nov 15;143(10):3200-6
references.pmid: 2478621
references.citation: Mol Biotechnol. 2007 Oct;37(2):146-54
references.pmid: 17914175
references.citation: Microb Pathog. 1994 Nov;17(5):323-37
references.pmid: 7723659
references.citation: J Immunol Methods. 2006 Feb 20;309(1-2):75-85
references.pmid: 16448665
references.citation: Vaccine. 2008 Jun 2;26(23):2925-9
references.pmid: 18440673
references.citation: J Infect Dis. 1997 Apr;175(4):839-46
references.pmid: 9086139
references.citation: Infect Immun. 2000 Mar;68(3):1450-6
references.pmid: 10678959
references.citation: Infect Immun. 2000 Oct;68(10):5889-900
references.pmid: 10992499
references.citation: Vaccine. 2011 Feb 11;29(8):1634-42
references.pmid: 21211592
references.citation: Vaccine. 2011 Nov 3;29(47):8689-95
references.pmid: 21906649
references.citation: J Infect Dis. 2000 Dec;182(6):1694-701
references.pmid: 11069242
references.citation: Infect Immun. 1990 Oct;58(10):3293-9
references.pmid: 1698178
references.citation: Lancet. 2007 Apr 7;369(9568):1179-86
references.pmid: 17416262
references.citation: Clin Infect Dis. 2009 Jul 15;49(2):205-12
references.pmid: 19508165
references.citation: Infect Immun. 1983 Feb;39(2):615-22
references.pmid: 6339385
references.citation: BMC Infect Dis. 2009 Aug 04;9:121
references.pmid: 19650933
references.citation: Anal Biochem. 1988 Nov 15;175(1):139-44
references.pmid: 3149873
references.citation: Arch Pediatr Adolesc Med. 2005 Feb;159(2):195-6
references.pmid: 15699318
references.citation: Clin Infect Dis. 2008 Jan 15;46(2):174-82
references.pmid: 18171247
references.citation: Anal Biochem. 1990 Feb 1;184(2):244-8
references.pmid: 2158246
references.citation: Clin Microbiol Infect. 2010 May;16(5):402-10
references.pmid: 20132251
references.citation: Infect Immun. 1999 Dec;67(12):6375-84
references.pmid: 10569753
references.citation: Expert Rev Vaccines. 2011 Aug;10(8):1143-67
references.pmid: 21810065
references.citation: Anal Biochem. 1994 Jun;219(2):335-40
references.pmid: 8080090
references.citation: J Med Microbiol. 2006 Feb;55(Pt 2):215-221
references.pmid: 16434715
references.citation: Vaccine. 2001 Sep 14;19(32):4780-90
references.pmid: 11535330
references.citation: J Med Microbiol. 2008 Mar;57(Pt 3):273-278
references.pmid: 18287288
references.citation: Microb Pathog. 1992 Oct;13(4):261-9
references.pmid: 1363703
references.citation: Vaccine. 2009 Jun 24;27(31):4136-41
references.pmid: 19406190
references.citation: Biopolymers. 2008 May;89(5):392-400
references.pmid: 17896349
references.citation: J Clin Invest. 1985 Jul;76(1):52-9
references.pmid: 3874882
references.citation: JAMA. 2007 Nov 14;298(18):2155-63
references.pmid: 18000199
references.citation: Expert Rev Vaccines. 2011 Nov;10(11):1621-31
references.pmid: 22043960
references.citation: Infect Immun. 2003 Jan;71(1):75-85
references.pmid: 12496151
references.citation: Vaccine. 2009 Jan 29;27(5):726-32
references.pmid: 19063929
references.citation: Infect Immun. 1999 Sep;67(9):4720-4
references.pmid: 10456922
references.citation: Infect Immun. 1991 May;59(5):1839-45
references.pmid: 1826897
references.citation: Appl Microbiol Biotechnol. 2012 May;94(3):683-94
references.pmid: 22075630
references.citation: Eur J Pediatr. 2010 Sep;169(9):1123-8
references.pmid: 20383524
references.citation: Anal Biochem. 1986 May 15;155(1):155-67
references.pmid: 3717552
references.citation: Infect Immun. 2004 Sep;72(9):5031-40
references.pmid: 15321996
references.citation: Anal Biochem. 1986 Mar;153(2):262-6
references.pmid: 3706709
references.citation: Vaccine. 2010 Aug 2;28(34):5513-23
references.pmid: 20600514